High levels of serum homocysteine in non-alcoholic steatohepatitis

Leach, N.; Dronca, Eleonora; Craciun, Cristina; Crişan, Dana

doi:10.1016/j.ejim.2016.06.018

Cited by 5 publications

(2 citation statements)

References 9 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are relatively few studies evaluating the serum levels of HCY in patients with NAFLD and NASH, showing contradictory results. The study of Leach NV et al (14) , showed a high level of HCY in NASH patients when compared to controls (12.73±3.43 μmol/L vs 9.95±2 μmol/L; P=0.001) and it was not caused by the deficiency of cofactors (the levels of the vitamins B6, B12 and folic acid were similar in both groups). These data are consistent with the metanalysis of Yining Dai et al (15) , that found eight studies totaling 935 participants (397 NAFLD cases and 538 controls), that evaluated the serum HCY levels and/or the levels of HCY -related vitamins.…”

Section: Discussionmentioning

confidence: 84%

Vitamin B12 and Homocysteine Levels in Patients With Nafld: A Systematic Review and Metanalysis

Costa

Guahnon

Seganfredo

et al. 2021

Arq. Gastroenterol.

View full text Add to dashboard Cite

BACKGROUND: The vitamin B12 absorption can be affected in patients with nonalcoholic fatty liver disease (NAFLD), and low serum vitamin B12 levels has been related to the high homocysteine (HCY) levels and to the degree of NAFLD. OBJECTIVE: To carry out a systematic review and metanalysis of serum vitamin B12 and HCY levels in patients with NAFLD. METHODS: Original studies including serum vitamin B12 and HCY levels in humans with NAFLD were included. The searches were performed in four databases. RESULTS: 159 studies were identified, and after excluding the duplicates and non-eligible titles, eight original articles were included. Six out of eight showed higher B12 levels in NAFLD patients (404.9±136.2 pg/mL in relation to controls 353.91±117.3 pg/mL). Seven of the eight studies also showed higher HCY levels in NAFLD patients (14.2±3.44 umol/L in relation to controls 11.05±3.6 umol/L). The results for serum vitamin B12 and HCY levels were submitted to metanalysis, showing no difference in the vitamin B12 levels between patients with NAFLD and controls. However, the levels of Hcy were higher in NAFLD patients than in controls. CONCLUSION: There was no relashionship between the vitamin B12 levels and NAFLD. The levels of HCY were significantly higher in patients with NAFLD, suggesting this could be a potential marker for liver damage.

show abstract

Section: Discussionmentioning

confidence: 84%

Vitamin B12 and Homocysteine Levels in Patients With Nafld: A Systematic Review and Metanalysis

Costa

Guahnon

Seganfredo

et al. 2021

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Одна из важных причин ДЭ -повышение уровня гомоцистеина (Hcy), которое возникает при нарушении обмена серосодержащих аминокислот, в частности S-аденозилметионина (SAM) [26]. Гипергомоцистеинемия у пациентов с НАЖБ подтверждена в исследовании Leach N.V. и соавт., которые выявили высокий уровень Hcy у пациентов с НАСГ по сравнению с контрольной группой (12,73±3,43 мкмоль/л против 9,95±2 мкмоль/л; P=0,001) [27]. Эти данные согласуются с метаанализом, проведенным Dai Y. и соавт., в который вошло 8 исследований, включивших «Рецепт», 2024, том 27, № 2 935 участников.…”

unclassified

Use of Ademethionine in General Medical Practice: Focus on Cardiovascular Risk

Пицко

2024

Рецепт

View full text Add to dashboard Cite

В последнее время наблюдается значительный рост случаев неалкогольной жировой болезни печени (НАЖБП). Имеются литературные данные о том, что НАЖБП является независимым фактором риска развития сердечно-сосудистых заболеваний и их осложнений. Причинными факторами сердечно-сосудистого риска, индуцированного НАЖБП, являются оксидативный стресс, субклиническое воспаление, инсулинорезистентность, дисфункция эндотелия и нарушение обмена серосодержащих аминокислот. Такие факторы риска, как артериальная гипертензия, дислипидемия, ожирение, сахарный диабет 2-го типа, часто сосуществуют с НАЖБП. Учитывая общность патогенетических механизмов, возможно предположить, что лечение заболевания печени может оказывать превентивный эффект в плане снижения сердечно-сосудистого риска. В связи с этим в данном обзоре приводится анализ взаимосвязи между НАЖБП и сердечно-сосудистой патологией и обсуждается возможная терапевтическая стратегия, включающая применение адеметионина для коррекции сердечно-сосудистого риска у пациентов с НАЖБП. Recently, there has been a significant increase in the incidence of non-alcoholic fatty liver disease (NAFLD). There is literature data that NAFLD is an independent risk factor for the development of cardiovascular diseases and their complications. Causal factors for NAFLD-induced cardiovascular risk include oxidative stress, subclinical inflammation, insulin resistance, endothelial dysfunction, and impaired sulfur-containing amino acid metabolism. Risk factors such as arterial hypertension, dyslipidemia, obesity, and type 2 diabetes mellitus often coexist with NAFLD. Given the commonality of pathogenetic mechanisms, it is possible to assume that treatment of liver disease may have a preventive effect in terms of reducing cardiovascular risk. In this regard, this review analyzes the relationship between NAFLD and cardiovascular pathology and discusses a possible therapeutic strategy involving the use of ademetionine to correct cardiovascular risk in patients with NAFLD.

show abstract

Homocysteine in nonalcoholic steatohepatitis: A reply

Polyzos

2016

European Journal of Internal Medicine

View full text Add to dashboard Cite

High levels of serum homocysteine in non-alcoholic steatohepatitis

Cited by 5 publications

References 9 publications

Vitamin B12 and Homocysteine Levels in Patients With Nafld: A Systematic Review and Metanalysis

Vitamin B12 and Homocysteine Levels in Patients With Nafld: A Systematic Review and Metanalysis

Use of Ademethionine in General Medical Practice: Focus on Cardiovascular Risk

Homocysteine in nonalcoholic steatohepatitis: A reply

Contact Info

Product

Resources

About